Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Stifel Downgrades Egalet (NASDAQ:EGLT) Rating to “Hold” from “Buy” With $1.5 Target

Stifel Nicolaus Analyst Rating Change Egalet NASDAQ:EGLT

Egalet (NASDAQ:EGLT) Downgrade

Egalet (NASDAQ:EGLT)’s rating was lowered by expert analysts at Stifel from a “Buy” rating to a “Hold” rating in analysts note sent to clients and investors on Wednesday, 3 January. The firm now has a $1.5 target price on the stock. Stifel’s target price indicates a potential upside of 53.06 %.

In spite of this rating downgrade NASDAQ:EGLT is right now trading 0.95% higher at $1.06 as of 12:07 AM New York time. Egalet shares have [From2] 0% over the last 200 days, while the S&P 500 has increased 6.00% over the same time period.

According to data compiled by Thomson Reuters, Egalet (NASDAQ:EGLT)’s stock is covered by 5 equity analysts across the Street, with 0 analysts giving it a Sell rating, 0 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $18.2, which reflects an upside potential of 1616.98% over the current price.

Institutional Ownership

Broadfin Capital Llc had the most significant stake with ownership of 1.13 million shares as of Q2 2015 for 0.77% of the stock exposure. Wall Street Associates is another very bullish fund who is having 228,890 shares of Egalet or 0.59% of their stock exposure. Furthermore, Sphera Funds Management Ltd. have 0.36% of their stock exposure invested in the company for 292,500 shares. The New Jersey-based fund New Jersey Better Educational Savings Trust revealed it had bought so far a stake worth about 0.26% of the fund’s stock portfolio in Egalet. The Maryland-based fund Rock Springs Capital Management Lp is also positive about the stock, possessing 54,000 shares or 0.14% of their stock exposure.

Egalet (NASDAQ:EGLT) Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray.

Egalet (NASDAQ:EGLT) traded up 0.95% on 3 January, hitting $1.06. A total of 780,177 shares of the company’s stock traded hands. This is up from average of 422,565 shares. Egalet has a 52 week low of $0.97 and a 52 week high of $10. The company has a market cap of $45.63M and a P/E ratio of 0.

Get the latest Egalet (NASDAQ:EGLT) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Stifel Downgrades Egalet (NASDAQ:EGLT) Rating to “Hold” from “Buy” With $1.5 Target appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Stifel Downgrades Egalet (NASDAQ:EGLT) Rating to “Hold” from “Buy” With $1.5 Target


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription